Filtered By:
Condition: Diabetes
Drug: Docetaxel
This page shows you your search results in order of date.
Order by Relevance | Date
Total 17 results found since Jan 2013.
< em > CYP3A < /em > genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study
Front Pharmacol. 2023 Jul 4;14:1178421. doi: 10.3389/fphar.2023.1178421. eCollection 2023.ABSTRACTBackground: Taxane-induced peripheral neuropathy (TIPN) is an important cause of premature treatment cessation and dose-limitation in cancer therapy. It also reduces quality of life and survivorship in affected patients. Genetic polymorphisms in the CYP3A family have been investigated but the findings have been inconsistent and contradictory. Methods: A systematic review identified 12 pharmacogenetic studies investigating genetic variation in CYP3A4*22 and CYP3A5*3 and TIPN. In our candidate gene study, 288 eligible participan...
Source: Cancer Control - July 20, 2023 Category: Cancer & Oncology Authors: Laurence McEvoy Joanne Cliff Daniel F Carr Andrea Jorgensen Rosemary Lord Munir Pirmohamed Source Type: research
Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action
Cell Mol Life Sci. 2022 Oct 4;79(11):539. doi: 10.1007/s00018-022-04551-4.ABSTRACTBreast cancer (BC) is one of the most common cancers in females and is responsible for the highest cancer-related deaths following lung cancer. The complex tumor microenvironment and the aggressive behavior, heterogenous nature, high proliferation rate, and ability to resist treatment are the most well-known features of BC. Accordingly, it is critical to find an effective therapeutic agent to overcome these deleterious features of BC. Resveratrol (RES) is a polyphenol and can be found in common foods, such as pistachios, peanuts, bilberries, ...
Source: Cell Research - October 4, 2022 Category: Cytology Authors: Mitra Behroozaghdam Maryam Dehghani Amirhossein Zabolian Davood Kamali Salar Javanshir Farzaneh Hasani Sadi Mehrdad Hashemi Teimour Tabari Mohsen Rashidi Sepideh Mirzaei Atefeh Zarepour Ali Zarrabi Danielle De Greef Anupam Bishayee Source Type: research
Fight Aging! Newsletter, May 2nd 2022
In this study, we tested the therapeutic potential of VHHASC and a newly generated VHH against murine ASC (VHHmASC) to target ASC specks in vitro and in vivo. We show that pre-incubation of extracellular ASC specks with VHHASC abrogated their inflammatory functions in vitro. Recombinant VHHASC rapidly disassembled pre-formed ASC specks and thus inhibited their ability to seed the nucleation of soluble ASC. Notably, VHHASC required prior cytosolic access to prevent inflammasome activation within cells, but it was effective against extracellular ASC specks released following caspase-1-dependent loss of membrane integrity, an...
Source: Fight Aging! - May 1, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
The potential value of amlexanox in the treatment of cancer: molecular targets and therapeutic perspectives
Biochem Pharmacol. 2021 Dec 27:114895. doi: 10.1016/j.bcp.2021.114895. Online ahead of print.ABSTRACTAmlexanox (AMX) is an azoxanthone drug used for decades for the treatment of mouth aphthous ulcers and now considered for the treatment of diabetes and obesity. The drug is usually viewed as a dual inhibitor of the non-canonical IκB kinases IKK-ɛ (inhibitor-kappaB kinase epsilon) and TBK1 (TANK-binding kinase 1). But a detailed target profile analysis indicated that AMX binds directly to twelve protein targets, including different enzymes (IKK-ɛ, TBK1, GRK1, GRK5, PDE4B, 5- and 12-lipoxygenases) and non-enzyme proteins (...
Source: Biochemical Pharmacology - December 30, 2021 Category: Drugs & Pharmacology Authors: Christian Bailly Source Type: research
TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer
CONCLUSION: MET addition failed to improve the standard DOCE regimen in mCRPC. Further research targeting tumor cell metabolism should be performed.PMID:34629300 | DOI:10.1016/j.clgc.2021.08.008
Source: Clinical Prostate Cancer - October 11, 2021 Category: Cancer & Oncology Authors: Marc Pujalte Martin Delphine Borchiellini Brice Thamphya Aline Guillot Jean-Baptiste Paoli Dominique Besson Werner Hilgers Frank Priou Claude El Kouri Benjamin Hoch Jean-Laurent Deville Renaud Schiappa Sandrine Cheli G érard Milano Jean-Fran çois Tanti Source Type: research
European Commission approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Basel, 23 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer.“This approval represents a significant step forward in the treatment of HER2-positive breast cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The innovation of Phesgo significantly reduces the ti...
Source: Roche Media News - December 23, 2020 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo ™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC injection.“The FDA approval of Phesgo reflects our commitment...
Source: Roche Media News - June 29, 2020 Category: Pharmaceuticals Source Type: news
FDA accepts Roche ’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (pharmacokinet ics)...
Source: Roche Investor Update - February 25, 2020 Category: Pharmaceuticals Source Type: news
